Summary
Axon Enterprise, Inc. (AXON) reported its first-quarter 2019 results, showcasing strong revenue growth driven by its Software and Sensors segment, which increased by 33.8% year-over-year. This segment's performance was bolstered by significant growth in Axon Evidence and cloud services, along with extended warranties. While overall net sales grew 14.4% to $115.8 million, the company experienced a notable decrease in income from operations, falling to $2.7 million from $13.6 million in the prior year's quarter. This decline is attributed to increased cost of sales and higher operating expenses, particularly in research and development and sales, general, and administrative functions, as the company invests in future growth. The introduction of the new TASER 7 device also contributed to higher initial production costs. Despite the reduction in operating income, Axon's balance sheet remains robust, with cash and cash equivalents standing at $223.6 million. The company has strategically shifted towards a subscription model for its products, which is expected to improve recurring revenue and customer engagement over the long term, although it impacts near-term liquidity. Management remains optimistic about the full-year outlook, projecting revenues between $485 million and $495 million, signaling continued expansion despite the short-term margin pressures.
Financial Highlights
48 data points| Revenue | $115.81M |
| Cost of Revenue | $46.89M |
| Gross Profit | $68.92M |
| R&D Expenses | $23.35M |
| SG&A Expenses | $42.89M |
| Operating Expenses | $66.25M |
| Operating Income | $2.67M |
| Net Income | $6.42M |
| EPS (Basic) | $0.11 |
| EPS (Diluted) | $0.11 |
| Shares Outstanding (Basic) | 58.91M |
| Shares Outstanding (Diluted) | 59.75M |
Key Highlights
- 1Total net sales increased by 14.4% to $115.8 million in Q1 2019, compared to $101.2 million in Q1 2018.
- 2The Software and Sensors segment experienced substantial growth, with net sales up 33.8% to $50.4 million, driven by Axon Evidence and cloud services, and extended warranties.
- 3Income from operations decreased significantly to $2.7 million from $13.6 million in the prior year, primarily due to increased investments in R&D and SG&A, and higher cost of sales.
- 4Net income was $6.4 million ($0.11 per diluted share), down from $12.9 million ($0.24 per diluted share) in the prior year's quarter.
- 5Cash and cash equivalents stood at $223.6 million as of March 31, 2019, though overall cash, cash equivalents, and restricted cash decreased due to investment purchases.
- 6The company is actively transitioning to a subscription-based model for its products, aiming for long-term recurring revenue growth.
- 7The TASER segment saw a modest 2.9% increase in net sales, influenced by the transition to the new TASER 7 device and associated initial production costs.